Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : At 24 weeks, data demonstrated that patients treated with RT001 (linoleic Acid) experienced less worsening (a 3.3-point reduction from baseline) in ALSFRS-R score as compared to greater worsening (4.6-point reduction from baseline) for the placebo group.
Brand Name : RT001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2022
Lead Product(s) : Linoleic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RT001 to impact the progression of INAD based on the compound’s demonstrated ability to down-regulate lipid peroxidation used in patients with infantile neuroaxonal dystrophy.
Brand Name : RT001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2021
Lead Product(s) : Linoleic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DHA
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.
Brand Name : RT011
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2020
Lead Product(s) : DHA
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Linoleic Acid
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Retrotope filed this IND for a PSP Phase 2/3 trial after 3 patients treated with RT001 in PSP Expanded Access protocols showed encouraging results after more than a year on drug.
Brand Name : RT001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2020
Lead Product(s) : Linoleic Acid
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RT001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A post-treatment tissue evaluation will determine if RT001 is capable of ameliorating inflammatory lung injury.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2020
Lead Product(s) : RT001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Linoleic Acid
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company stated that, RT001 has a synergistic downstream benefit in the pathophysiology of PSP. This orphan designation encourages clinical trials and rapid review of data from trials to treat PSP.
Brand Name : RT001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 18, 2020
Lead Product(s) : Linoleic Acid
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Linoleic Acid
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : With this trial, Retrotope expands its pipeline of indications for RT001 which is currently being studied in a pivotal trial in Infantile Neuroaxonal Dystrophy, which is fully enrolled.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2020
Lead Product(s) : Linoleic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?